# Atalanta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atalanta-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.atalantatx.com
- Total disclosed funding: $207M
- Latest round: Series B (Jan 28, 2025)
- Investors on record: 11

## About

Atalanta Therapeutics, Inc. is a US-based biotechnology firm focused on developing innovative RNA interference therapies for central nervous system diseases, especially targeting Huntington's disease and related disorders.Founded in 2018 and headquartered in Boston, US, Atalanta Therapeutics specializes in RNA interference therapies. The company has completed two investment rounds, with its latest being a Series B round where it raised USD 97.00 mn on January 28, 2025, primarily from EQT Life Sciences and Sanofi Ventures, along with other notable investors. The founder's background in biotechnology has led to a strong foundation for the company’s growth.Atalanta Therapeutics specializes in developing innovative therapies for central nervous system (CNS) diseases, particularly Huntington’s disease. The company utilizes proprietary di-siRNA technology to silence disease-causing genes, aiming to halt disease progression. Their interventions target genetic disorders such as Huntington's, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease, primarily focusing on North American and European markets.Atalanta Therapeutics operates with a combined B2B and direct-to-consumer model, generating revenue through collaborations with clinical trial sponsors and pharmaceutical partnerships. Their flagship product targets the HTT gene, with revenue structures involving upfront payments for research, milestone payments, and royalties from future sales. Specific pricing strategies and revenue figures are not publicly disclosed.With the recent Series B funding of USD 97.00 mn, Atalanta Therapeutics plans to advance its RNA interference therapies, specifically targeting KCNT1-related epilepsy and Huntington’s disease, through upcoming clinical trials and IND submissions. The company is focused on expanding its footprint in North America and Europe, aiming for broader market penetration by 2026.

## Funding rounds

- Series B, Jan 28, 2025, $97M — Aberdeen Investments, Novartis Venture Fund, EQT Life Sciences, RiverVest Ventures Partners, Gerald and Henrietta Rauenhorst Foundation, F-Prime Capital, Sanofi Ventures, Pictet Alternative Advisors, Mirae Asset Financial Group
- Series A, Jan 11, 2021, $110M — F-Prime Capital, Genentech, Inc., Biogen

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Genentech, Inc. — Series A
- Biogen — Series A
- Aberdeen Investments (https://capitalatlas.ai/funds/aberdeen-investments) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B
- Gerald and Henrietta Rauenhorst Foundation — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series B
- Mirae Asset Financial Group — Series B